fashion -WSS

fashion

author：fashion 2025-10-01 21:24:04 - browse：114

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Peter Hotez and the public health issue of online harassment

entertainment

WSS

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Why police arrested suspected Gilgo Beach killer away from his house

The new HIV moral panic

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

knowledge

fashion

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Congress likely to miss an opportunity to fix drug shortages issue

How to save PrEP access — and even expand it

Blood tests recalled over risk of missed heart attack diagnosis

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

At least 13 dead in Texas as scorching temps continue

Jerome Adams on the need for new antivirals for Covid

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

The high cost of giving birth even with insurance

BioMarin wins approval for gene therapy to treat hemophilia A

focus

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Continuity nursing helped my family in our darkest PICU moments

Does aspartame cause cancer? What new WHO guidance says

Malaria cases in Florida and Texas: Here’s what you need to know

How one medical school became remarkably diverse

Congress likely to miss an opportunity to fix drug shortages issue

focus

Wikipedia

entertainment

leisure time